A KM survival analysis also demonstrated that among patients with lung carcinomas and kidney cancers, high GPC4 expression was associated with better overall survival, while in patients with glioma, glioblastoma, pancreatic carcinoma, and uveal melanoma, those with high GPC4 expression had shorter survival times. This evidence concerns the gene GPC4 and central nervous system cancer.